Multiple Myeloma
Latest News in Multiple Myeloma
September 29, 2024
IMS 2024 Myeloma Oral Sessions Day 4
The final day of presentations at the International Myeloma Society (IMS) meeting in Brazil provided updates on the use of various treatments for patients with relapsed and refractory multiple myeloma. Let us break down the key findings for you… Antibody Drug Conjugate Therapy Blenrep (belanatamab mafodotin) Results of a large trial of Blenrep (belanatamab mafodotin), […]
September 28, 2024
IMS 2024 Myeloma Oral Sessions Day 3
The third day of presentations at the International Myeloma Society (IMS) meeting in Brazil offered a glimpse into the potential of new treatment strategies for patients with relapsed/refractory multiple myeloma (RRMM) and provided additional updates on quadruplet regiments for newly diagnosed multiple myeloma (NDMM). Talvey-Based Combinations for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Talvey (talquetamab), […]
September 27, 2024
IMS 2024 Myeloma Oral Sessions Day 2
Welcome to the second day of our recap of the latest findings on myeloma treatments reported at the International Myeloma Society (IMS) meeting in Rio De Janeiro, Brazil. Today gave us important updates on new treatment combinations for newly diagnosed multiple myeloma (NDMM), particularly patients ages 65 years and older, as well as a new […]
677 Active Multiple Myeloma Clinical Trials
677 Active Multiple Myeloma Clinical Trials
As of October 8, 2024
Source: clinicaltrials.gov
LOCATE
CLINICAL TRIALS
BROWSE
FDA-approved DRUGS